Source: PR Newswire

Press Release: Leap Therapeutics : Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Chris Mirabelli's photo - CEO of Leap Therapeutics

CEO

Chris Mirabelli

CEO Approval Rating

73/100

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more